Scholarlink

Purpose <p>Childhood obesity is a major global health concern associated with increased metabolic and cardiovascular risk. Although oat-derived beta-glucan has shown metabolic benefits in adults, evidence in pediatric populations remains limited. This study evaluated the effects of beta-glucan supplementation on anthropometric measures and cardiometabolic risk factors in children and adolescents with overweight and obesity.</p> Methods <p>In a randomized, double-blind, placebo-controlled trial, 86 participants aged 6–17 years with overweight or obesity were assigned to receive either 3&#xa0;g/day of oat-derived beta-glucan or an isocaloric starch placebo for 8 weeks. Anthropometric indices, glycemic and lipid profiles, liver enzymes, dietary intake, and physical activity were assessed at baseline and post-intervention. Between-group comparisons of change scores were performed using ANCOVA, adjusting for baseline values and relevant covariates.</p> Results <p>Seventy-three participants completed the study (beta-glucan: <i>n</i> = 34; placebo: <i>n</i> = 39). After 8 weeks, the beta-glucan group showed greater reductions in body weight, BMI, BMI-for-age z-score, waist circumference, and hip circumference compared with placebo (all adjusted-p-values &lt; 0.01). For selected biochemical outcomes, unadjusted between-group comparisons showed significantly greater reductions in fasting blood sugar (<i>p</i>-value = 0.04), triglycerides (p-value = 0.02), and ALT (p-value = 0.01) in the beta-glucan group. No significant differences were observed for insulin, HOMA-IR, LDL-C, HDL-C, or total cholesterol. Total energy intake decreased more substantially in the beta-glucan group than in the placebo group (<i>p</i> &lt; 0.001).</p> Conclusions <p>beta-glucan supplementation may improve body composition and selected cardiometabolic markers in children with overweight and obesity; however, the short intervention duration and modest effect sizes highlight the need for longer and more comprehensive trials.</p> Trial registration <p>The study was registered in the Iranian Registry of Clinical Trials (IRCT20180805040703N3; registration date: January 26, 2025).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of beta-glucan supplementation on anthropometric Indices, glycemic markers, lipid profile, and liver enzymes in children and adolescents with overweight and obesity: a randomized controlled trial

  • 期刊论文

  • 发表日期：

    2026年1月6日

查看全文
  • Mahdi Amani Farani,
  • Ali Nikparast,
  • Kimia Forouzan,
  • Mohammad Hassan Sohouli,
  • Sohrab Sali,
  • Maryam Razavi,
  • Pejman Rohani,
  • Golaleh Asghari

摘要

Purpose

Childhood obesity is a major global health concern associated with increased metabolic and cardiovascular risk. Although oat-derived beta-glucan has shown metabolic benefits in adults, evidence in pediatric populations remains limited. This study evaluated the effects of beta-glucan supplementation on anthropometric measures and cardiometabolic risk factors in children and adolescents with overweight and obesity.

Methods

In a randomized, double-blind, placebo-controlled trial, 86 participants aged 6–17 years with overweight or obesity were assigned to receive either 3 g/day of oat-derived beta-glucan or an isocaloric starch placebo for 8 weeks. Anthropometric indices, glycemic and lipid profiles, liver enzymes, dietary intake, and physical activity were assessed at baseline and post-intervention. Between-group comparisons of change scores were performed using ANCOVA, adjusting for baseline values and relevant covariates.

Results

Seventy-three participants completed the study (beta-glucan: n = 34; placebo: n = 39). After 8 weeks, the beta-glucan group showed greater reductions in body weight, BMI, BMI-for-age z-score, waist circumference, and hip circumference compared with placebo (all adjusted-p-values < 0.01). For selected biochemical outcomes, unadjusted between-group comparisons showed significantly greater reductions in fasting blood sugar (p-value = 0.04), triglycerides (p-value = 0.02), and ALT (p-value = 0.01) in the beta-glucan group. No significant differences were observed for insulin, HOMA-IR, LDL-C, HDL-C, or total cholesterol. Total energy intake decreased more substantially in the beta-glucan group than in the placebo group (p < 0.001).

Conclusions

beta-glucan supplementation may improve body composition and selected cardiometabolic markers in children with overweight and obesity; however, the short intervention duration and modest effect sizes highlight the need for longer and more comprehensive trials.

Trial registration

The study was registered in the Iranian Registry of Clinical Trials (IRCT20180805040703N3; registration date: January 26, 2025).